Sengenics and LifeCodexx partner to offer NIPT in Southeast Asia

Konstanz / January 3, 2017 – Sengenics, a leading molecular diagnostics and research services company in Southeastern Asia, and LifeCodexx AG, pioneer in cell-free fetal DNA testing in Europe, announced today that they have formed a partnership in the field of non-invasive prenatal testing (NIPT). Through this cooperation, pregnant women in Malaysia, Singapore, Thailand, Brunei, Vietnam, UAE and Middle East will have access to LifeCodexx’ proprietary PrenaTest® NIPT technologies.

 

Read more

LifeCodexx receives CE mark for its novel NIPT solution based on methylation-specific quantitative PCR

Konstanz, December 7, 2016 – LifeCodexx AG, Europe’s first NIPT provider, announced today CE marking of its PrenaTest® BioIT analysis software based on an innovative methylation-specific qPCR assay for the detection of fetal trisomy 21 (qNIPT). Now the proprietary PrenaTest® software is cleared for the analysis of data from next generation sequencing as well as from qPCR.

 

Read more

Elucigene Diagnostics and Lifecodexx Partner to Offer NIPT in UK and Ireland

Elucigene Diagnostics, developer and distributor of leading prenatal and human genetics diagnostics and LifeCodexx AG, pioneer in cell-free fetal DNA testing in Europe, announced today (26th October 2016) that they have partnered. Through this cooperation, UK and Irish patients will have access to LifeCodexx’ proprietary PrenaTest® NIPT technology.

 

Read more

PrenaTest® one step closer to statutory reimbursement in Germany

The Federal Joint Committee starts procedure for method validation of non-invasive prenatal tests   Constance, August 19, 2016, Germany – PrenaTest®, Europe´s first non-invasive molecular genetic prenatal diagnostic test (NIPT) for the determination of the most common chromosomal disorders in unborn children, is likely to be reimbursed within the near future by statutory health insurances […]

 

Read more

LifeCodexx AG enhances PrenaTest® availability in Switzerland and Germany through successful technology transfers and strategic partnerships

Innovative PrenaBoxx® provides local NIPT software analysis solution for both NGS- and qPCR-related analysis technologies

Constance, March 16, 2016 – LifeCodexx AG today announced that it has recently teamed up with several leading laboratory groups in Switzerland and Germany in order to transfer LifeCodexx’ proprietary NIPT technology to the new partners. Through the cooperation agreements, the access to PrenaTest®, Europe’s first non-invasive prenatal test (NIPT), will significantly be enhanced for gynecologists in the German-speaking regions via extensive medical customer and support networks provided by the partner labs.

 

Read more

Novel qPCR-based PrenaTest® successfully validated in clinical study

Konstanz, Germany, December 1, 2015 –LifeCodexx AG reported today the successful validation of its innovative qPCR-based NIPT assay designed to determine fetal trisomy 21 from maternal blood. The blinded study with close to 700 samples demonstrates clearly that the accuracy of the new qPCR-based PrenaTest® is superior to the accuracy of the combined test and comparable to the performance of current non-invasive prenatal tests based on next generation sequencing or microarrays.

 

Read more

PrenaTest® is now reimbursed by Swiss statutory health insurance programs

Constance, Germany – Now many pregnant women who are insured in Switzerland could benefit from the PrenaTest®. As the first non-invasive prenatal test in Europe for the detection of chromosomal disorders from maternal blood it will be reimbursed by the statutory health insurance (OKP) in Switzerland starting July 15, 2015. This decision was made by the Federal Department of Home Affairs (EDI) on recommendation of the Swiss Federal Office of Public Health (BAG).

 

Read more

1 2 3
top